NANOBIOTIX SA - ADR (NBTX) Stock Price, Forecast & Analysis
USA - NASDAQ:NBTX - US63009J1079 - ADR
NBTX Key Statistics, Chart & Performance
The current stock price of NBTX is 17.7 USD. In the past month the price decreased by -22.3%. In the past year, price increased by 321.43%.
NBTX Latest News, Press Relases and Analysis
NBTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.15 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About NBTX
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
NANOBIOTIX SA - ADR
60 rue de Wattignies
Paris ILE-DE-FRANCE 75012 FR
CEO: Dr. Laurent Levy
Employees: 103
Phone: 33140260470
NANOBIOTIX SA - ADR / NBTX FAQ
What does NANOBIOTIX SA - ADR do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
What is the current price of NBTX stock?
The current stock price of NBTX is 17.7 USD. The price decreased by -15.19% in the last trading session.
What is the dividend status of NANOBIOTIX SA - ADR?
NBTX does not pay a dividend.
How is the ChartMill rating for NANOBIOTIX SA - ADR?
NBTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is NANOBIOTIX SA - ADR (NBTX) stock traded?
NBTX stock is listed on the Nasdaq exchange.
Would investing in NANOBIOTIX SA - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NBTX.
Can you provide the ownership details for NBTX stock?
You can find the ownership structure of NANOBIOTIX SA - ADR (NBTX) on the Ownership tab.
NBTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NBTX. When comparing the yearly performance of all stocks, NBTX is one of the better performing stocks in the market, outperforming 98.86% of all stocks.
NBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NBTX. NBTX has a bad profitability rating. Also its financial health evaluation is rather negative.
NBTX Financial Highlights
Over the last trailing twelve months NBTX reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS decreased by -47.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NBTX Forecast & Estimates
12 analysts have analysed NBTX and the average price target is 22.09 USD. This implies a price increase of 24.81% is expected in the next year compared to the current price of 17.7.
For the next year, analysts expect an EPS growth of 48.11% and a revenue growth 70.64% for NBTX